The BRAFi-resistant primary melanoma cells show features of slow-cycling cells, e.g., mesenchymal morphology, reduced proliferation and migration, increased resistance to chemotherapeutic agents, i.e., cisplatin and etoposide, as well as altered cell cycle profile and levels of cell cycle regulators [106], implying that the specific p53 isoform expression pattern could correlate with specific features of BRAFi-resistant melanoma cells. The gene discussed is TP53; the disease is melanoma.